RetinalGenix Technologies Inc.

OTC: RTGN · Healthcare · Medical - Devices

PublicHQ Apollo Beach, CACIK 0001836295Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 2DQ —GM —SS 37

v0.1 · 35/100 weight · pillars only

↑ market scale, filing timeliness · ↓ return on assets, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$2.4M

Employees

—

as of 2026-08-18

Market cap

$75.4M

as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$2.4M-$2.4M2025

Total assets$21.0k$21.0k2025

Liabilities$2.3M$2.3M2025

Equity-$2.3M-$2.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is RetinalGenix Technologies Inc.’s financial profile?

RetinalGenix Technologies Inc. earned -$2.4M in FY2025 net income.

Peers · Healthcare

Adicet Bio, Inc.——Dogwood Therapeutics, Inc.——Telomir Pharmaceuticals, Inc. Common Stock——Cingulate Inc.——Instinct Bio Technical Co. Holdings Inc.——PMV Pharmaceuticals, Inc.——

Key facts

CEOJerry Katzman

SectorHealthcare

IndustryMedical - Devices

HeadquartersApollo Beach, CA

ExchangeOTC: RTGN

Employees—

IPO date2022-02-24

Latest filings

10-Q2026-08-14 8-K2026-07-15 10-Q2026-05-20 10-K2026-04-15 8-K2026-03-26 10-Q2025-11-14 10-Q2025-08-19 10-Q2025-05-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.